This study evaluated the effect of topiramate (TPM) on the quality of life (QOL) in childhood epilepsy, using the Korean quality of life in childhood epilepsy (K-QOLCE) questionnaire. An open label, prospective, observational study of the families of 664 children with epilepsy from 41 centers was conducted. The parents completed the K-QOLCE at the baseline visit and again 6. months after starting TPM treatment. The parents reported the seizure frequency at both assessment dates. Statistically significant improvements in all K-QOLCE domains except social functioning were found at 6. months after starting TPM treatment from the baseline-scores (P< 0.05). However, improved QOL scores were not dependent on the reduction in seizure frequency. TPM significantly improved QOL in children with epilepsy, suggesting its potential clinical benefits.
Bibliographical noteFunding Information:
Study (ID.TOPATEPY4054) was funded by Janssen, Korea Ltd., a Johnson and Johnson company. The remaining authors have no conflicts of interest.
This investigation was supported by Janssen, Korea, Ltd ., a Johnson and Johnson company Research Fund ( ID. TOPATEPY4054 ). Gratitude is expressed to the investigators and to their sites that provided patients for the study.
All Science Journal Classification (ASJC) codes
- Pediatrics, Perinatology, and Child Health
- Developmental Neuroscience
- Clinical Neurology